Amazon Receives FDA Warning Letter For OTC Mole Removal Products
The FDA’s Center for Drug Evaluation and Research released a warning letter sent to Amazon Inc’s (NASDAQ:AMZN) CEO Andy Jassy for selling…
NeuroOne Medical Shares Fall After EEG Electrode Regulatory Update
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has submitted a special 510(k) to the FDA for its sEEG electrode to extend the duration…
NeuroOne Seeks Again FDA Clearance For sEEG Electrode In Brain Mapping Diagnostics
NeuroOne Medical Technologies (NASDAQ: NMTC) has submitted a special 510(k) to the U.S. Food and Drug Administration (FDA) for its sEEG electrode to extend the duration of use from less than 24 hours to less than 30 day use.
QIAGEN Highlights Launch
https://corporate.qiagen.com/English/newsroom/press-releases/press-release-details/2022/QIAGEN-launches-new-solutions-that-significantly-accelerate-DNA-variant-detection-and-RNA-sequencing-of-low-input-samples/default.as
FDA Pushes Decision Date For Reata’s Genetic Neuromuscular Disease Candidate
The FDA has extended the review timeline for Reata Pharmaceuticals Inc’s (NASDAQ:RETA) marketing application seeking approval for omaveloxolone for Friedreich’s ataxia by…
Verona Pharma To Announce Top-Line Data From Phase 3 ENHANCE-2 Trial Of Nebulized Ensifentrine For COPD
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report top-line Phase 3 data from
Kodiak Sciences Completes Enrollment In GLOW Phase 3 Clinical Trial Of Tarcocimab Tedromer (KSI-301) In Patients With Non-Proliferative Diabetic Retinopathy
odiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has
uardant Health Announces New Data From Portfolio Of Blood Tests And GuardantINFORM Real-World Clinical-Genomic Platform At IASLC 2022 World Conference On Lung Cancer
Presentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific mutations on treatment efficacy, and informing therapeutic
FDA Asks For Additional Study For Acadia’s Pimavanserin In Alzheimer’s-Associated Delusions
The FDA has issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals Inc (NASDAQ:ACAD) regarding its supplemental marketing application for pimavanserin in…